BACKGROUND: Lipocalin-2, a 25-kDa secreted glycoprotein, is a useful biomarker for early detection of various renal injuries. Because lipocalin-2 is abundantly expressed in adipose tissue and liver, we investigated its relevance to obesity-related pathologies. METHODS: We used real-time PCR and in-house immunoassays to quantify the mRNA and serum concentrations of lipocalin-2 in C57BL/KsJ db/db obese mice and their age- and sex-matched lean littermates. We analyzed the association between serum lipocalin-2 concentrations and various metabolic and inflammatory variables in 229 persons (121 men and 108 women) recruited from a previous cross-sectional study, and we evaluated the effect of the insulin-sensitizing drug rosiglitazone on serum lipocalin-2 concentrations in 32 diabetic patients (21 men and 11 women). RESULTS: Compared with the lean littermates, lipocalin-2 mRNA expression in adipose tissue and liver and its circulating concentrations were significantly increased in db/db diabetic/obese mice (P <0.001). These changes were normalized after rosiglitazone treatment. In humans, circulating lipocalin-2 concentrations were positively correlated (P <0.005) with adiposity, hypertriglyceridemia, hyperglycemia, and the insulin resistance index, but negatively correlated (P = 0.002) with HDL cholesterol. There was also a strong positive association between lipocalin-2 concentrations and high sensitivity C-reactive protein (hs-CRP), independent of age, sex, and adiposity (P = 0.007). Furthermore, rosiglitazone-mediated decreases in lipocalin-2 concentrations correlated significantly with increases in insulin sensitivity (r = 0.527; P = 0.002) and decreases in hs-CRP concentrations (r = 0.509; P = 0.003). CONCLUSIONS: Lipocalin-2 is an inflammatory marker closely related to obesity and its metabolic complications. Measurement of serum lipocalin-2 might be useful for evaluating the outcomes of various clinical interventions for obesity-related metabolic and cardiovascular diseases.
BACKGROUND:Lipocalin-2, a 25-kDa secreted glycoprotein, is a useful biomarker for early detection of various renal injuries. Because lipocalin-2 is abundantly expressed in adipose tissue and liver, we investigated its relevance to obesity-related pathologies. METHODS: We used real-time PCR and in-house immunoassays to quantify the mRNA and serum concentrations of lipocalin-2 in C57BL/KsJ db/db obesemice and their age- and sex-matched lean littermates. We analyzed the association between serum lipocalin-2 concentrations and various metabolic and inflammatory variables in 229 persons (121 men and 108 women) recruited from a previous cross-sectional study, and we evaluated the effect of the insulin-sensitizing drug rosiglitazone on serum lipocalin-2 concentrations in 32 diabeticpatients (21 men and 11 women). RESULTS: Compared with the lean littermates, lipocalin-2 mRNA expression in adipose tissue and liver and its circulating concentrations were significantly increased in db/db diabetic/obesemice (P <0.001). These changes were normalized after rosiglitazone treatment. In humans, circulating lipocalin-2 concentrations were positively correlated (P <0.005) with adiposity, hypertriglyceridemia, hyperglycemia, and the insulin resistance index, but negatively correlated (P = 0.002) with HDL cholesterol. There was also a strong positive association between lipocalin-2 concentrations and high sensitivity C-reactive protein (hs-CRP), independent of age, sex, and adiposity (P = 0.007). Furthermore, rosiglitazone-mediated decreases in lipocalin-2 concentrations correlated significantly with increases in insulin sensitivity (r = 0.527; P = 0.002) and decreases in hs-CRP concentrations (r = 0.509; P = 0.003). CONCLUSIONS:Lipocalin-2 is an inflammatory marker closely related to obesity and its metabolic complications. Measurement of serum lipocalin-2 might be useful for evaluating the outcomes of various clinical interventions for obesity-related metabolic and cardiovascular diseases.
Authors: Anca D Dobrian; David C Lieb; Banumathi K Cole; David A Taylor-Fishwick; Swarup K Chakrabarti; Jerry L Nadler Journal: Prog Lipid Res Date: 2010-10-21 Impact factor: 16.195
Authors: Monika Gonzalez; Whitney Sealls; Elliot D Jesch; M Julia Brosnan; Istvan Ladunga; Xinxin Ding; Paul N Black; Concetta C DiRusso Journal: Physiol Genomics Date: 2010-11-23 Impact factor: 3.107
Authors: Meilian Liu; Lijun Zhou; Aimin Xu; Karen S L Lam; Michael D Wetzel; Ruihua Xiang; Jingjing Zhang; Xiaoban Xin; Lily Q Dong; Feng Liu Journal: Proc Natl Acad Sci U S A Date: 2008-11-14 Impact factor: 11.205
Authors: David C Lieb; Joshua J Brotman; Margaret A Hatcher; Myo S Aye; Banumathi K Cole; Bronson A Haynes; Stephen D Wohlgemuth; Mark A Fontana; Hind Beydoun; Jerry L Nadler; Anca D Dobrian Journal: J Clin Endocrinol Metab Date: 2014-06-23 Impact factor: 5.958
Authors: N Hesselbarth; A Kunath; M Kern; M Gericke; N Mejhert; M Rydén; M Stumvoll; M Blüher; N Klöting Journal: Int J Obes (Lond) Date: 2017-07-24 Impact factor: 5.095
Authors: Salamah Mohammad Alwahsh; Min Xu; Hatice Ali Seyhan; Shakil Ahmad; Sabine Mihm; Giuliano Ramadori; Frank Christian Schultze Journal: World J Gastroenterol Date: 2014-02-21 Impact factor: 5.742